Meet us at the ISN-WCN 23 "World Congress of Nephrology" in Bangkok, 30 March – 2 April 2023!

Logo TauroLock


Depending on the patient’s needs, we offer a range of specialised catheter lock solutions. TauroLock™-Hep100 is the right option for those who have previously benefited from heparin as an anti-occlusive agent.


Indication and effect

TauroLock™-Hep100 has been approved for instillation in all central-venous access systems. This lock solution prevents the formation of a bacterial biofilm and thereby protects patients from catheter-related infections. At the same time, it ensures a high patency rate. We recommend TauroLock™-HEP100 for CVCs in oncology and parenteral nutrition.


TauroLock™-Hep100 contains three active ingredients:


  • taurolidine
  • heparin (100 units per ml)
  • citrate (4 %)


Taurolidine has a broad antimicrobial activity (incl. MRSA and VRE) against gram-positive and gram-negative bacteria and fungi (e.g. Candida). Heparin and citrate both help to prevent occlusions within the catheter.


In-between treatment sessions, TauroLock™-Hep100 is instilled into the saline-flushed access system. Please note that medical staff must check the filling volume of the respective catheter or port system.

Expert recommendations


Taurolidine-based lock solutions such as TauroLock™-HEP100 are recommended in national and international guidelines. For patients suffering from heparin-induced thrombocytopenia (HIT), we offer two heparin-free alternatives:




Patients diagnosed with HIT should not use TauroLock™-Hep100 for their vascular access system (VAD). Instead, we recommend TauroLock™ and/ or TauroLock™-U25.000. Furthermore, TauroLock™ is not suitable if:


  • patients have displayed a hypersensitive reaction to citrate or taurolidine
  • patients are taking medication which interferes with either citrate, heparin, or taurolidine.


TauroLockTM-HEP100 must be aspirated before the next treatment. 

Package sizes

Our customers may obtain TauroLock™-Hep100 in ampoules of 3 ml (single dose, 10 ampoules per box).

Storage & transport

TauroLock™-Hep100 must be stored at 15 °C to 30 °C. Please note that you must not freeze TauroLock™-Hep100 under any circumstances.

More information about TauroLock™-HEP100


For national guideline recommendations, e.g. GPOH 2018:

“Lock solutions containing taurolidine are recommended for the prevention of CVAD-associated infections.”

Download GPOH recommendations for TauroLock™-HEP100 in oncology

21.4 Taurolidine for the Prophylaxis against CVAD-related Infection

Lock solutions containing Taurolidine are recommended for the prevention of CVAD-associated Infections (scientific evidence Cat. IB, problem: reimbursement in outpatient care).

Taurolidine containing lock solutions are also recommended for paediatric-oncologic patients on cyclized (home-)parenteral nutrition if an infusion-free interval of at least 4 hours is available (Cat. IB for patients on home-parenteral nutrition).

23.6.3 Taurolidine-Lock for adjuvant therapy

Taurolidine (e.g. 1.35% Taurolidine, 4% Citrate) can be used as adjuvant measure during systemic treatment with antibiotics (Cat. II). The minimal dwell time in the catheter lumen is 4 hours.

Download study by Tribler et al. on TauroLock™-HEP100 in parenteral nutrition (2017)

“…In patients with intestinal failure who are life dependent on HPS, the taurolidine-citrate-heparin catheter lock demonstrates a clinically substantial and cost-beneficial reduction of CRBSI occurrence in a high-risk population compared with heparin…”

Download study by Handrup et al. on lock solutions in oncology (2013)

“…Locking of long-term tunneled CVC with taurolidine significantly reduces catheter-related bloodstream infections in children with cancer...“

For personal inquiries, you can also contact us via phone or email.

Our international distributors based in more than 50 countries are happy to offer support ASAP.